Scope of report
- The report provides a snapshot of the global therapeutic landscape of Friedreich’s ataxia.
- The report assesses Friedreich’s ataxia pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Friedreich’s ataxia pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Friedreich’s ataxia ranging from discovery to pre-registration and undisclosed stages.
MIGENIX, Edison Pharmaceuticals, Warren Pharmaceuticals, Biovista, STATegics, Catabasis Pharmaceuticals, RaNA Therapeutics, Agilis Biotherapeutics, Repligen Corporation, Voyager Therapeutics, Bioblast Pharma, Retrotope, Cardero Therapeutics, Jupiter Orphan Therapeutics
Indolepropionic acid, Alfatradiol, LU AA 24493, A 0001, RG 2833, AGIL FA, Omaveloxolone, RT 001, Epicatechin, Trans-resveratrol oral, Epicatechin, Trans-resveratrol oral, Epicatechin, Trans-resveratrol oral, Epicatechin, Trans-resveratrol oral
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800